Department of Neurosurgery, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo, 663-8501, Japan.
Department of Neurosurgery, Sapporo Teishinkai Hospital, Sapporo, Japan.
Neurosurg Rev. 2021 Apr;44(2):935-944. doi: 10.1007/s10143-020-01259-6. Epub 2020 Feb 21.
Although endovascular or surgical treatment has been performed for preventing the rupture of saccular cerebral aneurysms (sCA), in some patients, the aneurysms may recur and require retreatment. We aimed to investigate the clinical and radiological outcomes of treating recurrent sCA. We retrospectively evaluated the data of 52 patients with 60 recurrent sCAs who were retreated and 1534 patients with 1817 sCAs who received initial treatment. The primary outcome was a recurrence of the aneurysm. Secondary outcomes were an additional treatment, rupture after treatment, and a neurological worsening, which was defined as an increase of 1 or more scores using the modified Rankin Scale at 12-month. Safety outcomes included postoperative ischemic and hemorrhagic complications. We compiled the 120 (60 each) propensity score-matched cohort based on a propensity score for the treatment of recurrent sCA. In the propensity score-matched cohort, recurrence after treatment was observed in 25% and 6.7% of cases in the retreatment and initial treatment groups, respectively. The odds ratio of recurrence after treatment was 4.7 (95% CI, 1.4-15; P = 0.011). The secondary and safety outcomes were not significantly different between the two groups. This study showed that the treatment of recurrent sCA was a risk factor for recurrence after treatment but not for additional treatment, rupture after treatment, or neurological worsening. Although decision-making regarding the treatment varies depending on the institutional protocols and personal experience of the physicians, endovascular or surgical retreatment could be performed without hesitation.
尽管已经对囊状脑动脉瘤(sCA)进行了血管内或手术治疗,以预防其破裂,但在一些患者中,动脉瘤可能会复发并需要再次治疗。我们旨在研究治疗复发性 sCA 的临床和影像学结果。我们回顾性评估了 52 例 60 个复发性 sCA 患者和 1534 例 1817 个初次治疗 sCA 患者的数据。主要结局是动脉瘤复发。次要结局是需要额外治疗、治疗后破裂和神经恶化,定义为使用改良 Rankin 量表在 12 个月时增加 1 分或更多。安全性结局包括术后缺血和出血并发症。我们根据复发性 sCA 的治疗倾向得分,编制了 120 个(每组 60 个)倾向得分匹配队列。在倾向得分匹配队列中,治疗后复发分别发生在再次治疗组和初次治疗组的 25%和 6.7%的病例中。治疗后复发的优势比为 4.7(95%CI,1.4-15;P=0.011)。两组的次要和安全性结局没有显著差异。本研究表明,复发性 sCA 的治疗是治疗后复发的危险因素,但不是额外治疗、治疗后破裂或神经恶化的危险因素。尽管治疗决策取决于机构方案和医生的个人经验,但可以毫不犹豫地进行血管内或手术再次治疗。